Partnering To Our Future Business Partners
Nihon Pharmaceutical Co., Ltd, as a member of the Takeda Pharmaceutical Group, which is the leading pharmaceutical company group in Japan, continues to grow as a unique company specializing in manufacturing, developing and marketing “plasma fractionation products” as well as in a basic and niche fields including of “gastrointestinal medications” and “disinfectants” etc.


We are looking for an opportunity to establish business alliances with companies that are considering exporting own products into the Japanese market or licensing proprietary technologies or drug candidates in order to deliver innovative new drugs to patients as early as possible through the strong sales network of Takeda Pharmaceutical.


NPO-15(TK21) is discovered by Nihon Pharmaceutical Research Laboratories for the treatment of Myasthenia Gravis with innovative mechanisms of action, which is available for out-licensing.

On Apr. 13, 2019, Nihon’s new drug candidate NPO-15 for the treatment of Myasthenia Gravis has been adopted by AMED’s Drug Discovery Support Program for Orphan drug prior to the Designation.

Download PDF

out-licensing available
Compound Code Product Summary Target Indication Development Stage Patent No. Original Article
NPO-15(TK-21) Product_summary_of_NPO-15(TK-21) Myasthenia Gravis Pre-Clinical PCT/JP2012/058912 Neurotherapeutics
If you are interested in either in- or out-licensing alliance with us, please contact the following email address and let us know your proposal.